"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 8 | 11 |
| 1997 | 3 | 8 | 11 |
| 1998 | 3 | 7 | 10 |
| 1999 | 1 | 6 | 7 |
| 2000 | 2 | 5 | 7 |
| 2001 | 1 | 8 | 9 |
| 2002 | 2 | 4 | 6 |
| 2003 | 2 | 4 | 6 |
| 2004 | 4 | 7 | 11 |
| 2005 | 5 | 11 | 16 |
| 2006 | 2 | 7 | 9 |
| 2007 | 1 | 6 | 7 |
| 2008 | 2 | 9 | 11 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 8 | 9 |
| 2011 | 1 | 12 | 13 |
| 2012 | 4 | 6 | 10 |
| 2013 | 2 | 7 | 9 |
| 2014 | 2 | 7 | 9 |
| 2015 | 2 | 4 | 6 |
| 2016 | 7 | 8 | 15 |
| 2017 | 3 | 6 | 9 |
| 2018 | 5 | 6 | 11 |
| 2019 | 5 | 5 | 10 |
| 2020 | 7 | 9 | 16 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 8 | 9 |
| 2024 | 3 | 5 | 8 |
| 2025 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025 Oct 10; 43(29):3209-3220.
-
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025 Dec; 26(8):626-641.
-
3D genome organization shapes DNA damage susceptibility to platinum-based drugs. Nucleic Acids Res. 2025 May 22; 53(10).
-
Chemotherapy and the somatic mutation burden of sperm. JCI Insight. 2025 Jun 23; 10(12).
-
DNA damage causes ATM-dependent heterochromatin loss leading to nuclear softening, blebbing, and rupture. Mol Biol Cell. 2025 Mar 01; 36(3):br6.
-
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 11; 10(11):1565-1570.
-
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 09 28; 404(10459):1240-1252.
-
Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy. JAMA Oncol. 2024 Jul 01; 10(7):912-922.
-
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024 Jun 10; 23(1):121.
-
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.